Reduced 60-Gy Radiation Maintains Control in HPV Oropharyngeal Cancer

The management of human papillomavirus-associated oropharyngeal carcinoma is currently transitioning from uniform, intensive protocols toward personalized, de-escalated strategies [1, 2]. While standard chemoradiotherapy achieves high cure rates, the associated long-term toxicities significantly impair quality of life for a patient population that is often younger and has fewer comorbidities than those with tobacco-related disease [3, 4]. Landmark trials such as De-ESCALaTE and RTOG 1016 have demonstrated that traditional treatment may represent over-treatment for these highly radiosensitive tumors, although the targeted agent cetuximab resulted in inferior outcomes compared to the standard cisplatin backbone [5, 2]. Specific evidence now supports the use of 60 grays of intensity-modulated radiotherapy (a precise form of radiation that conforms to the tumor shape) combined with weekly low-dose cisplatin, which maintains excellent 3-year tumor control while preserving patient function [6]. Furthermore, the ECOG 3311 trial established that primary surgery allows for a reduction in adjuvant radiation to 50 grays in intermediate-risk patients without compromising oncologic safety [7]. The durability of these regimens is supported by the NRG-HN002 trial, where post-treatment imaging demonstrated a negative predictive value (the probability that a negative test result truly indicates the absence of disease) of over 90% for 2-year locoregional control [8].